1. Гинекология: национальное руководство. Под ред. В.И.Кулакова, И.Б.Манухина, Г.М.Савельевой. М.: ГЭОТАР-Медиа, 2011; с. 704–24.
2. Bebear C, Barbeyrac B, Pereyre S. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801–5.
3. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195–7.
4. Carvalho FM, Aguiar FN, Tomioka R. Functional endometrial polyps in infertile asymptomatic patients: a possible evolution of vascular changes secondary to endometritis. Eur J Obstet Gynecol Reprod Biol 2013.
5. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: RR12.
6. Check JH, Choe JK, Amui J. Evaluation of the importance of late follicular phase endometrial echo patterns and pregnancy outcome following embryo transfer by evaluating infertile donor/recipient pairs. Clin Exp Obstet Gynecol 2011; 38 (4): 318–9.
7. Check JH. Comparison of pregnancy rate following in vitro fertilization-embryo transfer between the donors and the recipients in a donor oocyte program. J Assist Reprod Genet 1992; 9 (3): 248–50.
8. Chen PC, Tseng TC, Hsieh JY, Lin HW. Association between stroke and patients with pelvic inflammatory disease: a nationwide population-based study in Taiwan. Stroke Jul 2011; 42 (7): 2074–6.
9. Cicinelli E, De Ziegler D, Nicoletti R. Poor reliability of vaginal and endocervical cultures for evaluating microbiology of endometrial cavity in women with chronic endometritis. Gynecol Obstet Invest 2009; 68 (2): 108–15.
10. European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.org
11. Haggerty CL, Ness RB. Newrest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007; 44 (7): 953–60.
12. Heystek M, Ross JD. PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
13. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.
14. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676–9.
15. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475–84.
16. Kasius JC, Fatemi HM, Bourgain C. The impact of chronic endometritis on reproductive outcomes. Fertil Steril 2011; 96 (6): 1451–6.
17. Lauper U. Adnexitis and pelvic inflammatory disease. Gynakol Geburtshilfliche Rundsch 2005; 45 (1): 14–8.
18. Lin HW, Tu YY, Lin SY et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900–4.
19. Liou TH, Wu CW, Hao WR et al. Risk of myocardial infarction in women with pelvic inflammatory disease. Int J Cardiol 2012; 20.
20. Miron ND et al. Bacretiological agents which play a role in the development of infertility. Acta Microbiol Immunol Hung 2013; 60 (1): 41–53.
21. Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999; 43 (1): 12–5.
22. RCOG Green Top Guidelines – Management of Pelvic Inflammatory Disease 2003, 2009. http://www.rcog.org.uk
23. Ross JD, Cronjé HS, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi-centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446–51.
24. Solomkin J, Zhao YP, Ma EL. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.
25. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynecol Obstet 2008; 102 (2): 132–6.
26. Stein GE, Schooley S, Tyrrell KL. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008; 14 (1): 8–12.
27. Sweet RL. Pelvic inflammatory disease: current concepts of diagnosis and management. C Infect Dis Rep 2012.
28. Taylor B, Ness R, Darville T. Microbial correlates of delayed care for pelvic inflammatory disease. Sex Transm Dis 2011; 38 (5): 434–8.
29. Trent M, Bass D, Ness RB. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Trans Dis 2011; 8 (9): 879–81.
30. Wiesenfeld HC, Hillier SL, Meyn LA. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 2012; 120 (1): 37–43.
31. World Health Organization. Sexually transmitted infections. http://www.who.int/mediacentre/factsheets/fs110/en

А.В.Шуршалина

Университет Тафтса, США